Mark Chao

Stanford, California, United States Contact Info
2K followers 500+ connections

Join to view profile

Activity

Join now to see all activity

Experience & Education

  • Scorpion Therapeutics

View Mark’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Volunteer Experience

  • The Leukemia & Lymphoma Society Graphic

    Board Member, Silicon Valley and Monterey Bay Chapter

    The Leukemia & Lymphoma Society

    - Present 4 years 7 months

    Health

  • Board Member, Board of Governors

    Stanford Medicine Alumni Association

    - Present 2 years 11 months

    Education

Publications

  • A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

    Theranostics

    Other authors
    • Chu TW
    • Zhang R
    • Yang J
    • Shami PJ
    • Kopecek J
    See publication

  • Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab

    American Journal of Hematology

    Other authors
    • Hong J
    • Kunder C
    • Lester L
    • Schrier SL
    • Majeti R
    See publication

  • Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists

    Blood

    Other authors
    • Yakimchuk J
    • Hasni MS
    • Guan J
    • Sander B
    • Okret S

  • Two faces of ET: CALR and JAK2

    Blood

    Other authors
    • gotlib j
    See publication

  • Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies

    Cancer Management Research

  • The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

    Proceedings of the National Academy of Sciences

    Other authors
    • Willingham SB
    • Volkmer JP
    • Gentiles AJ
    • Sahoo D
    • van der Rijn M
    • Sunwoo JB
    • Alizadeh AA
    • Clarke MF
    • Weissman IL

  • The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

    Current Opinions in Immunology

    Other authors
    • Weissman IL
    • Majeti R

  • Programmed cell removal: a new obstacle in the road to developing cancer

    Nature Reviews Cancer

    Other authors
    • Majeti R
    • Weissman IL

  • Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

    Blood

    Other authors

  • Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

    Proceedings of the National Academy of Sciences

    Other authors
    • Jan M
    • Cha AC
    • Alizadeh AA
    • Gentiles AJ
    • Weissman IL
    • Majeti R

  • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

    Blood

    Other authors
    • Kohrt HE
    • Houot R
    • Goldstein M
    • Weiskopf K
    • Alizadeh AA
    • Brody J
    • Muller A
    • Pachynski RK
    • Czerwinski D
    • Coutre S

  • Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia

    Cancer Research

    Other authors
    • Alizadeh AA
    • Tang C
    • Jan M
    • Weissman-Tsukamoto R
    • Zhao F
    • Park CY
    • Weissman IL
    • Majeti R

  • Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

    Science Translational Medicine

    Other authors
    • Jaiswal S
    • Weissman-Tsukamoto R
    • Alizadeh AA
    • Gentles AJ
    • Volkmer J
    • Park CY
    • Majeti R
    • Weissman IL

  • Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

    Cell

    Other authors
    • Alizadeh AA
    • Tang C
    • Myklebust J
    • Varghese B
    • Gascoyne RD
    • Lossos IS
    • Levy R
    • Weissman IL
    • Majeti R

  • Macrophages as mediators of tumor immunosurveillance

    Trends in Immunology

    Other authors
    • Jaiswal S
    • Majeti R
    • Weissman IL

  • CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells

    Cell

    Other authors
    • Majeti R
    • Alizadeh AA
    • Pang W
    • Jaiswal S
    • Gibbs K
    • van Rooijien N
    • Weissman IL

  • CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

    Cell

    Other authors
    • Jaiswal S
    • Jamieson CH
    • Pang WW
    • Park CY
    • Majeti R
    • Traver D
    • Weissman IL

  • The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

    Proceedings of the National Academy of Sciences

    Other authors
    • Jamieson CH
    • Gotlib J
    • Durocher JA
    • Mariappan MR
    • Lay M
    • Zehnder JL
    • Lilleberg SL
    • Weissman IL

  • Heme oxygenase in Candida albicans is regulated by hemoglobin and is necessary for metabolism of exogenous heme and hemoglobin to alpha-biliverdin

    Journal of Biological Chemistry

    Other authors
    • Pendrak ML
    • Yan SS
    • Roberts DD

More activity by Mark

View Mark’s full profile

  • See who you know in common
  • Get introduced
  • Contact Mark directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Others named Mark Chao in United States

18 others named Mark Chao in United States are on LinkedIn

See others named Mark Chao

Add new skills with these courses

See all courses